GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Valuation Rank

Oncternal Therapeutics (FRA:GTU) Valuation Rank


View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Oncternal Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (FRA:GTU) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Valuation Rank
Comparable Companies
SLGL GDTC UBX SNSE LPCN FBRX SER PYPD CNTX ZIVO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
ONCT:USA
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Website
https://www.oncternal.com
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.